Research brief
Bristol Myers Squibb closed at 60.74 USD for the week ended 17 July, up 5.5% and only 2.5% below its 52-week high of 62.29 USD. The weekly Trend Signal is active and Relative Strength is positive, helped by a 13.7% four-week gain, yet activity pressure remains negative at -0.29 and volume was only moderately above the 13-week average.
- BMY ranked first for the week within US Drug Manufacturers - General, outpacing an industry average weekly return of roughly 0.0% and a Healthcare sector average of -0.7%.
- The stock sits 5.8% above its weekly Trend Line at 57.43 USD and 23.5% above Sharemaestro Fair Value at 49.19 USD, placing it high in its one-year range.
- Participation was constructive but not emphatic, with 61.1M shares traded, equal to 1.1x the 13-week average and 0.9x the 52-week average.
- Risk evidence is mixed: positive weeks have averaged 3.5% versus average losses of -2.1%, but downside weeks still outnumber upside weeks 27 to 25 over the past year.
Weekly move puts BMY ahead of large drugmaker peers
Bristol Myers Squibb finished the week at 60.74 USD, up 5.5%, giving it the strongest weekly return among the 20-stock US Drug Manufacturers - General group. That stands out against a flat industry average weekly return of 0.02% and a weaker US Healthcare sector average of -0.74%.
Trend Signal is active, but the setup is not one-sided
The Sharemaestro read is balanced, with a composite score of 58. BMY is above its 57.43 USD weekly Trend Line by 5.8%, and the Trend Signal is active after one week. Trend breadth for the stock is 55.8%, with 29 active weeks in the past 52, broadly consistent with the industry’s 55.0% trend breadth but better than the Healthcare sector’s 48.0%.
Momentum has improved near the high
The latest advance lifts BMY to 92.6% of its 52-week range, only 2.5% below the 62.29 USD high and well above the 41.45 USD low. The four-week return of 13.7% is the clearest momentum evidence, while the 12-week gain is more restrained at 3.5%, suggesting the move is recent rather than a smooth quarter-long climb.
Market Dynamics still ask for confirmation
Relative Strength is positive at 6.41, helped by the stock’s week ranking in the top tier of US Healthcare at the 89th percentile. The caution is that activity pressure remains negative at -0.29, so the move has Relative Strength support but not a clean Market Dynamics confirmation. Volume also sits in the middle: 61.1M shares were above the 55.9M 13-week average, but below the 64.6M 52-week average.
Risk and what to watch next
The main opportunity evidence is price holding above the Trend Line while approaching the 52-week high. The main risk evidence is the negative activity-pressure reading, a negative next-week expectancy of 43.94% for similar setup states, and one recent reversal marker in the smart-money tape. Next week, the key tests are whether BMY can press through the high-water area with stronger participation, whether activity pressure turns positive, and whether the Trend Line remains intact if the move cools.
Research note
This article is for educational market research only and is not financial, investment, trading, tax, or legal advice. Sharemaestro does not make buy, sell, or hold recommendations.
Source and attribution
Source: Sharemaestro. Canonical article: https://sharemaestro.com/news/bmy-drugmaker-week-rank-near-52-week-high/.
Media and research systems can follow the RSS feed or JSON feed.